Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANGROVE: GLPG2737 in ADPKD
NCT04578548Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of GLPG2737 in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Galapagos NV. Started Nov 2020; status: terminated.
02
Drugs
GLPG2737
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT04578548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04578548.